Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease
-
Published:2023-12
Issue:6
Volume:104
Page:1219-1226
-
ISSN:0085-2538
-
Container-title:Kidney International
-
language:en
-
Short-container-title:Kidney International
Author:
Chan Kam Wa,
Smeijer J. David,
Schechter MeirORCID,
Jongs Niels,
Vart Priya,
Kohan Donald E.,
Gansevoort Ron T.,
Liew Adrian,
Tang Sydney C.W.ORCID,
Wanner ChristophORCID,
de Zeeuw Dick,
Heerspink Hiddo J.L.ORCID
Funder
AbbVie
University of Hong Kong
China Medical Board
Reference39 articles.
1. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K;Abbott;Diabetes Care,2011
2. Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes;Gylfadottir;Pain,2020
3. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes;Davies;Diabetes Care,2006
4. Prevalence of pain and association with quality of life, depression and glycaemic control in patients with diabetes;Bair;Diabet Med,2010
5. Clinical pharmacology considerations in pain management in patients with advanced kidney failure;Davison;Clin J Am Soc Nephrol,2019
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献